DR-TB | MSF SAMU

SAMU Summaries

No resources currently available.

Guidelines
- MSF TB Guideline (2014)
  
  Read more
  
  MSF TB Guideline: English
  
  2_MSF TB Guidelines_2014_ENG.pdf
  
  MSF TB Guideline: French
  
  2_MSF TB Guidelines_2014_FR.pdf
- WHO: Guideline on DRTB (2016)
  
  Read more
  
  WHO: Guideline on DRTB
  
  WHO_DRTB_guidelines_2016.pdf
- WHO: Companion Handbook to the Guidelines on the Management of DRTB
  
  Read more
  
  WHO: Companion Handbook to the Guidelines on the Management of DRTB
  
  5_Companion Handbook to WHO guidelines on DR TB revised version.pdf
- WHO: The use of delamanid in the treatment of multidrug-resistant tuberculosis
  
  Read more
  
  WHO: The use of delamanid in the treatment of multidrug- resistant tuberculosis
  
  WHO_use_of_delamanid.pdf
- WHO: The use of bedaquiline in the treatment of multidrug-resistant tuberculosis
  
  Read more
  
  WHO: The use of bedaquiline in the treatment of multidrug-resistant tuberculosis
  
  WHO_use_of_bedaquiline.pdf
- endTB Guidelines on the Use of New Drugs in the Management of DRTB
  
  Read more
  
  endTB Guidelines on the Use of New Drugs in the Management of DRTB
  
  EndTB Guide for New TB Drugs Version 4.0.pdf
- MSF HIV/TB Clinical Guide for Primary Care 2018
  
  Read more
  
  MSF HIV/TB Clinical Guide for Primary Care
  
  MSF HIVTB Clinical Guide for Primary Care_December 2018.pdf

Implementation Resources
- MSF TB Patient Education and Counselling Flipchart: DS-TB, MDR-TB & XDR-TB Messages
  
  Read more
  
  TB Patient Education and Counselling Flipchart: DS-TB, MDR-TB & XDR-TB Messages
  
  MSFCH DSTB.DRTB_.XDRTB - Flipchart oct2016.pdf
- Counselling toolkit for DRTB (Khayelitsha)
  
  Read more
  
  Counselling toolkit for DRTB (Khayelitsha)
  
  Patient support DRTB_Khayelitsha_FINAL.pdf
- WHO: Policy Implementation package for new TB drug introduction (2014)
  
  Read more
  
  WHO: Policy Implementation package for new TB drug introduction
  
  WHO_policy_Implementation_package_new_DRTB_Drugs.pdf

Training Resources
A 12 module TB and DRTB E-Learning course, covering both clinical and programmatic aspects of TB and DRTB is available free, on and off line. It takes approximately 10 hours to complete and is available in English and French. For further details, click here and to register please email samu.elearning@joburg.msf.org.

SAMU hosts an annual one week face-to-face training for DRTB in Cape Town. For full details, click here.

endTB offers a 6-module E-Learning Training to provide guidance to physicians caring for MDR-TB patients enrolled in the endTB project on the use of new and re-purposed drugs. To access the endTB E-Learning, click here.
No resources currently available.

Want to Know More
For further information on DRTB go to the following websites

http://www.msf-tb-symposium.org/2017en/

https://www.msfaccess.org/our-work/tuberculosis

http://www.stoptb.org/

http://www.who.int/tb/en/

https://www.theunion.org/
- Out of Step: TB policies in 29 countries (2017)
  
  Read more
  
  Out of Step: TB policies in 29 countries
  
  TB_Report_OutOfStep_3rdEd_ENG_2017.pdf
- Self-administered therapy for DRTB treatment: Experience from MSF Khayelitsha, South Africa
  
  Read more
  
  Self-administered therapy for DRTB treatment: Experience from MSF Khayelitsha, South Africa
  
  MSF_SAT_DRTB_Khayelitsha.pdf
- Decentralisation of DRTB treatment: Experience from MSF in Swaziland
  
  Read more
  
  Decentralisation of DRTB treatment: Experience from MSF in Swaziland
  
  Decentralisation of DRTB care-2013_OCG_Swazilan.pdf
- endTB Interim Analysis: July 2018
  
  Read more
  
  endTB Interim Analysis
  
  endTB interim analysis (13 July 2018).pdf
- MSF DRTB abstracts from the UNION conference 2017
  
  Read more
  
  Delamanid for rifampicin resistant tuberculosis an observational cohort study from Khayelitsha
  
  1. Delamanid for rifampicin resistant tuberculosis an observational cohort study from Khayelitsha.pdf
  
  Adverse events over 6 months with delamanid in a programmatic setting in Khayelitsha
  
  2. Adverse events over 6 months with delamanid in a programmatic setting in Khayelitsha.pdf
  
  Accelerating access to delamanid for rifampicin-resistant tuberculosis in Khayelitsha, South Africa
  
  3. Accelerating access to delamanid for rifampicin-resistant tuberculosis in Khayelitsha, South Africa.pdf
  
  Early safety and efficacy of Bedaquiline and Delamanid combination for drug-resistant TB in Armenia, India and South Africa
  
  4. Combination BDQ and DLM late breaker Union2017.pdf

Additional resources

No resources currently available.

Corrections

No resources currently available.

Updates

No resources currently available.